There are few data on the best combination antiretroviral therapy in patients with HIV infection who need cancer chemotherapy because of drug–drug interactions and increased risk of toxic effects.
Methods
We evaluated the safety, efficacy and interactions of a raltegravir (RAL)-based regimen in 30 HIV-infected patients who received antineoplastic agents.
Results
A total of 17 patients had a non-AIDS-defining malignancy (7 with Hodgkin disease) and 13 had an HIV-related cancer (9 non-Hodgkin lymphoma, 2 Kaposi sarcoma and 2 anal cancer). Overall, they received 49 cycles of chemotherapy with 19 different antineoplastic drugs, including antimetabolites in 4 patients (5-FU, gemcitabine), alkylating agents in 10 cases (cyclophosphamide, ifosfamide), vinca alkaloids in 17 patients (vincristine, vinblastine), anti-tumour antibiotics in 18 cases (doxorubicin), cisplatin or carboplatin in 6, and monoclonal antibodies in 13 patients (rituximab, trastuzumab, cetuximab). Six patients modified the doses of antineoplastic agents due to toxicity not related to raltegravir. During a median follow-up of 67.8 patient-years (median 170 days in concomitant therapy) there was only 1 case of virological failure and no patient discontinued RAL. Geometric mean trough levels of RAL were 143 ng/ml (79–455). There were no opportunistic infections, median CD4+ T-cell count increased by 49 cells/ml and four (13%) patients died during the study (not related to AIDS progression).
Conclusions
Our results show that a RAL-based regimen is safe and effective in patients requiring chemotherapy, irrespective of type and of duration of chemotherapy.
References
1.
BarbaroG., BarbariniG.HIV infection and cancer in the era of highly active antiretroviral therapy (Review).Oncol Rep2007; 17: 1121–1126.
2.
OriolA., RiberaJ.M., BrunetS., del PotroE., AbellaE., EsteveJ.Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study.Haematologica2005; 90: 990–992.
3.
MounierN., KatlamaC., CostagliolaD., ChichmanianR.M., SpanoJ P.Drug interactions between antineoplastic and antiretroviral therapies: implications and management for clinical practice.Crit Rev Oncol Hematol2009; 72: 10–20.
4.
RudekM.A., FlexnerC., AmbinderR F.Use of antineoplastic agents in patients with cancer who have HIV/AIDS.Lancet Oncol2011; 12: 905–912.
5.
RockstrohJ.K., DeJesusE., LennoxJ.L.Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.J Acquir Immune Defic Syndr2013; 63: 77–85.
6.
SteigbigelR.T., CooperD.A., TepplerH.Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.Clin Infect Dis2010; 50: 605–612.
7.
RizkM.L., HouleR., ChanG.H., HafeyM., RheeE.G., ChuX.Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.Antimicrob Agents Chemother2014; 58: 1294–1301.
8.
PoirierJ.M., RobidouP., JaillonP.Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection.J Chromatogr B Analyt Technol Biomed Life Sci2008; 867: 277–281.
9.
FulcoP.P., HynickaL., RackleyD.Raltegravir-based HAART regimen in a patient with large B-cell lymphoma.Ann Pharmacother2010; 44: 377–382.
10.
JohnsonM.Raltegravir use in special populations.Eur J Med Res2009; 14Suppl 3: 43–46.
11.
TorresH.A., RallapalliV., SaxenaA.Efficacy and safety of antiretrovirals in HIV-infected patients with cancer.Clin Microbiol Infect2014; 20: O672–O679.
12.
LittleR.F., PittalugaS., GrantN.Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.Blood2003; 101: 4653–4659.
13.
KaplanL.D., StrausD.J., TestaM.A.Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.N Engl J Med1997; 336: 1641–1648.
14.
AntinoriA., CingolaniA., AlbaL.Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy.AIDS2001; 15: 1483–1491.
15.
VaccherE., SpinaM., TalaminiR.Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy.Clin Infect Dis2003; 37: 1556–1564.
16.
VaccherE., SpinaM., di GennaroG.Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.Cancer2001; 91: 155–163.
17.
RatnerL., LeeJ., TangS.Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.J Clin Oncol2001; 19: 2171–2178.
18.
EzzatH.M., CheungM.C., HicksL.K.Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma.Leuk Lymphoma2012; 53: 2390–2396.
19.
RizkM.L., HangY., LuoW.L.Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients.Antimicrob Agents Chemother2012; 56: 3101–3106.
20.
KurzM., StoeckleM., KrasniqiF., BattegayM., MarzoliniC.Etravirine: a good option for concomitant use with chemotherapy for Hodgkin's lymphoma.Int J STD AIDS2015; 26: 212–214.
21.
CasadoJ.L., BanonS., RodriguezM.A., MorenoA., MorenoS.Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.Antiviral Res2015; 113: 103–106.
